Crispr Therapeutics AG (CRSP) Gets a Buy Rating from William Blair

William Blair analyst Raju Prasad maintained a Buy rating on Crispr Therapeutics AG (CRSPResearch Report) yesterday. The company’s shares closed last Monday at $73.71.

According to, Prasad is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -5.0% and a 40.5% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Rocket Pharmaceuticals, and Allogene Therapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Crispr Therapeutics AG with a $98.94 average price target, representing a 29.7% upside. In a report released today, JMP Securities also maintained a Buy rating on the stock with a $100.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Based on Crispr Therapeutics AG’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $178K and GAAP net loss of $179 million. In comparison, last year the company earned revenue of $202K and had a GAAP net loss of $113 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

CRISPR Therapeutics AG engages in the development and commercialization of therapies derived from genome-editing technology. Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow in 2014 and is headquartered in Zug, Switzerland.

Read More on CRSP:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More